

# Whole Exome Sequencing Analysis

Patient name	: Mr. XXX	PIN	: XX
Gender/ Age	: Male/ 36 Years	Sample number	: XX
Referring clinician	: XX	Sample collection date	: XX
Specimen	: Peripheral Blood	Sample receipt date	: XX
		Report date	: XX

## Clinical history

Proband, Mr. XXX was born to non-consanguineous couple. He was presented with chief complaints of seizures since 16 years of age and on medications. His MRI brain in 2023 indicative of multiple cortical and subcortical T2 hyperintense lesions involving bilateral cerebral hemispheres, few FLAIR hyperintense linear radial band in bilateral white matter and mild diffuse calvarial thickening with sclerosis of mastoid air cells. His EEG in 2023 indicative of normal study. His urea and creatinine levels indicative of normal levels. Proband, Mr. XXX is suspected to be affected with neurocutaneous syndrome or Hyperprolactinemia or tuberous sclerosis and has been evaluated for pathogenic variations.

## Results

Pathogenic variant causative of the reported phenotype was detected

List of significant variant identified related to the phenotype:

Gene	Region	Variant*	Allele Status	Disease	Classification*	Inheritance pattern
TSC1 (-)	Exon 17	c.2074C>T (p.Arg692Ter)	Heterozygous	Tuberous sclerosis-1 (OMIM#191100)	Pathogenic	Autosomal Dominant

\*Genetic test results are based on the recommendation of American college of Medical Genetics [1].  
No other variant that warrants to be reported for the given clinical indication was identified.

## Interpretation

### ***TSC1*: c.2074C>T**

**Variant summary:** A heterozygous stop gained variation in exon 17 of the *TSC1* gene (chr9:g.132903785G>A, NM\_000368.5, Depth: 101x) that results in the premature truncation of the protein at codon 692 (p.Arg692Ter) was detected. This variant is a stop gained variant which occurs in an exon of *TSC1* upstream of where nonsense mediated decay is predicted to occur. This variant is predicted to cause loss of normal protein function through protein truncation.

**Population frequency:** This variant has not been reported in gnomAD database and 1000 genomes database.

**Clinvar and Literature evidence:** This variant has been previously classified as pathogenic in ClinVar database [3]. The observed variant has previously been reported in patients affected with Tuberous sclerosis [4].

**In-silico prediction:** The *in-silico* predictions of the variant are deleterious by CADD. The reference codon is conserved across mammals in PhyloP and GERP++ tools.

**OMIM phenotype:** Tuberous sclerosis-1 (OMIM#191100) is caused by heterozygous mutation in the *TSC1* gene (OMIM\*605284). This disease follows autosomal dominant pattern of inheritance. Tuberous sclerosis complex (TSC) is a multisystem disorder characterized by hamartomas in multiple organ systems, including the brain, skin, heart, kidneys, and lung. Central nervous system manifestations include epilepsy, learning difficulties, behavioral problems, and autism. Renal lesions, usually angiomyolipomas, can cause clinical problems secondary to hemorrhage or by compression and replacement of healthy renal tissue, which can cause renal failure. Patients can also develop renal cysts and renal-cell carcinomas. Pulmonary lymphangiomyomatosis can develop in the lungs. Skin lesions include melanotic macules, facial angiofibromas, and patches of connective tissue nevi. There is a wide clinical spectrum, and some patients may have minimal symptoms with no neurologic disability [2].

**Variant classification:** Based on the evidence, this variant is classified as a pathogenic variant. **In this view, clinical correlation and familial segregation analysis are strongly recommended to establish the significance of the finding. If the results do not correlate, additional testing may be considered based on the phenotype observed.**

## **Recommendations**

- Sequencing the variant(s) in the parents and the other affected and unaffected members of the family is recommended to confirm the significance.
- Alternative test is strongly recommended to rule out the deletion/duplication.
- Genetic counselling is advised.

## **Methodology**

DNA extracted from the blood was used to perform whole exome using whole exome capture kit. The targeted libraries were sequenced to a targeted depth of 80 to 100X using GenoLab M sequencing platform. This kit has deep exonic coverage of all the coding regions including the difficult to cover regions. The sequences obtained are aligned to human reference genome (GRCh38.p13) using Sentieon aligner and analyzed using Sentieon for removing duplicates, recalibration and re-alignment of indels. Sentieon DNAScope has been used to call the variants. Detected variants were annotated and filtered using the VarSeq software with the workflow implementing the ACMG guidelines for variant classification. The variants were annotated using 1000 genomes (V2), gnomAD (v3.1.2.1.1), ClinVar, OMIM, dbSNP, NCBI RefSeq Genes. *In-silico* predictions of the variant was carried out using VS-SIFT, VS-PolyPhen2, PhyloP, GERP++, GeneSplicer, MaxEntScan, NNSplice, PWM Splice Predictor. Only non-synonymous and splice site variants found in the coding regions were used for clinical interpretation. Silent variations that do not result in any change in amino acid in the coding region are not reported.

### Sequence data attributes

Total reads generated	8.40 Gb
Data ≥ Q30	97.43 %

Genetic test results are reported based on the recommendations of American College of Medical Genetics [1], as described below:

Classification	Interpretation
Pathogenic	A disease-causing variation in a gene which can explain the patients’ symptoms has been detected. This usually means that a suspected disorder for which testing had been requested has been confirmed
Likely Pathogenic	A variant which is very likely to contribute to the development of disease however, the scientific evidence is currently insufficient to prove this conclusively. Additional evidence is expected to confirm this assertion of pathogenicity.
Variant of Uncertain Significance	A variant has been detected, but it is difficult to classify it as either pathogenic (disease causing) or benign (non- disease causing) based on current available scientific evidence. Further testing of the patient or family members as recommended by your clinician may be needed. It is probable that their significance can be assessed only with time, subject to availability of scientific evidence.

## Disclaimer

---


- The classification of variants of unknown significance can change over time. Anderson Diagnostics and Labs cannot be held responsible for it.
- Intronic variants, UTR, Promoter region variants and CNV are not assessed using this assay.
- Certain genes may not be covered completely, and few mutations could be missed. Variants not detected by this assay may impact the phenotype.
- The variations have not been validated by Sanger sequencing.
- The above findings and result interpretation was done based on the clinical indication provided at the time of reporting.
- It is also possible that a pathogenic variant is present in a gene that was not selected for analysis and/or interpretation in cases where insufficient phenotypic information is available.
- Genes with pseudogenes, paralog genes and genes with low complexity may have decreased sensitivity and specificity of variant detection and interpretation due to inability of the data and analysis tools to unambiguously determine the origin of the sequence data in such regions.
- Incidental or secondary findings that meet the ACMG guidelines can be given upon request [5].

## References


---

1. Richards, S, et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine: official journal of the American College of Medical Genetics. 17.5 (2015): 405-424.
2. Amberger J, Bocchini CA, Scott AF, Hamosh A. McKusick's Online Mendelian Inheritance in Man (OMIM). Nucleic Acids Res. 2009 Jan;37(Database issue):D793-6. doi: 10.1093/nar/gkn665. Epub 2008 Oct 8.
3. <https://www.ncbi.nlm.nih.gov/clinvar/variation/VCV000048885.59>
4. Pilipow K, et al. Monoallelic germline *TSC1* mutations are permissive for T lymphocyte development and homeostasis in tuberous sclerosis complex individuals. PLoS One. 2014 Mar 14;9(3):e91952. doi: 10.1371/journal.pone.0091952. Erratum in: PLoS One. 2019 Jun 7;14(6):e0218354. PMID: 24633152; PMCID: PMC3954840.
5. Kalia S.S. et al., Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med., 19(2):249-255, 2017.

**This report has been reviewed and approved by:**



Sivasankar.S, Ph.D  
Molecular Biologist



Muthukumaran. S, Ph.D  
Clinical Bioinformatician



Sachin. D.Honguntikar, Ph.D,  
Molecular Geneticist



Dr. G. Suriyakumar  
Director